Moderna shares fall 7% to $135.22 as traders engage in profit-taking after a 392% year-to-date surge; BioNTech falls 4%, Merck falls 1%.
Moderna (MRNA) shares fell 7% to $135.22 in early trading Monday, after rising 392% year-to-date, as traders opted for profit-taking in the absence of new negative catalysts. Over the same period, BioNTech (BNTX) shares fell 4% to $111.47, and Merck (MRK) shares fell 1% to $150.61.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
EU trade chief holds talks in China amid trade tensions, EU Parliament votes for tougher stance
-
2
BitMart Exchange Has Ceased Operations: A Review of Perpetual Contract Services and Platform Status
-
3
Polkadot (DOT) Ecosystem Expansion: New Projects, Core Upgrades, and Tokenomics Transformation
-
4
TXBIT Coin Status Analysis: Token Market and Risks After the Closure of the Original Txbit Exchange
-
5
Overview of Cryptocurrency Exchanges Supporting USDT Stablecoin
-
6
China's Cryptocurrency Regulatory Policies and a Global Overview of Trading Platforms
-
7
Casper (CSPR) Token Analysis: The State of Enterprise Blockchains and Market Considerations
-
8
AI Debt Frenzy Triggers Credit Market Alarm: SpaceX Seeks $40 Billion in Funding, 10-Year US Treasury Yield Surpasses 5.3% to Hit New High Since 2002
-
9
DCR Coin: Decred Token Trading Platforms and Purchase Guide
-
10
In-depth Analysis of CAKE Token Market Capitalization Trends: PancakeSwap Ecosystem and Deflationary Mechanism
Markets Today
Recommended Reading










